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Introduction
Colorectal cancer is nowadays the third most prominent form of  cancer and the second cause of  death 
in developed countries. The lack of  therapies that can efficiently control the disease urges the explora-
tion of  novel avenues to find promising targets for new drugs. It is well established that chronic gut 
inflammation is a foundation for tumor initiation and progression (1). Patients with inflammatory 
bowel diseases, especially ulcerative colitis (UC), are at higher risk for colon cancer, and the use of  
antiinflammatory drugs reduces its incidence (2, 3). During the development of  inflammation-associ-
ated cancers, the interaction between the epithelial cells that harbor mutations in proto-oncogenes or 
tumor-suppressor genes, and the microenvironment enriched in proinflammatory mediators, benefit 
tumor growth (4). Mediators such as IL-23 activate mitogenic pathways that trigger the expansion of  
premalignant clones (5). Also, stimulation of  the IL-23 receptor in innate and adaptive immune cells 
induces the production of  IL-17 that, either directly or via induction of  other inflammatory cytokines 
and chemokines, contributes to the generation of  a tumor microenvironment in which tumor sup-
pressive cells are repressed (6, 7). In this scenario, the recruitment of  innate immune cells by chemo-
kines such as CXCL1 or CXCL2 further contributes to exacerbating the protumorigenic environment 
(8). From these data it is clear that a better knowledge of  the pathways implicated in the expression 
of  proinflammatory genes in intestinal immune cells could help to design new strategies to restrain 
inflammation-associated malignancies.
Colon cancer is a devastating illness that is associated with gut inflammation. Here, we explored 
the possible role of lipin-1, a phosphatidic acid phosphatase, in the development of colitis-
associated tumorigenesis. Azoxymethane and dextran sodium sulfate–treated (DSS-treated) 
animals deficient in lipin-1 harbored fewer tumors and carcinomas than WT animals due to 
decreased cellular proliferation, lower expression of antiapoptotic and protumorigenic factors, and 
a reduced infiltration of macrophages in colon tumors. They also displayed increased resistance to 
DSS-induced colitis by producing less proinflammatory cytokines and experiencing less immune 
infiltration. Lipin-1–deficient macrophages from the colon were less activated and displayed 
lower phosphatidic acid phosphatase activity than WT macrophages isolated from DSS-treated 
animals. Transference of WT macrophages into lipin-1–deficient animals was sufficient to increase 
colitis burden. Furthermore, treatment of lipin-1–deficient mice with IL-23 exacerbated colon 
inflammation. Analysis of human databases from colon cancer and ulcerative colitis patients 
showed that lipin-1 expression is increased in those disorders and correlates with the expression 
of the proinflammatory markers CXCL1 and CXCL2. And finally, clinically, LPIN1 expression had 
prognostic value in inflammatory and stem-cell subtypes of colon cancers. Collectively, these data 
demonstrate that lipin-1 is a critical regulator of intestinal inflammation and inflammation-driven 
colon cancer development.
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Lipids are well established as key modulators of  immune responses. Many of  them function as bioac-
tive extracellular and intracellular molecules that bind to membrane receptors or change the localization 
or activation of  signaling proteins during immune cell activation (9, 10). Interestingly, de novo synthesis 
of  lipids has also been described as an important event during the differentiation and activation of  innate 
immune cells such as macrophages (11). While much effort has been devoted to demonstrating that lipid 
mediators like COX-2–derived prostaglandin E2 are important for tumor growth and development in the 
colon (12, 13), other lipids and their related enzymes, and more specifically, enzymes that drive de novo 
lipid synthesis, have received less attention in the context of  gut inflammation and tumorigenesis.
During the last few years, our laboratory has been involved in delineating the role that a family of  
enzymes of  the de novo lipid biosynthesis pathway, the lipins, has in proinflammatory responses (14–17). 
Lipins possess phosphatidic acid (PA) phosphohydrolase activity that produces diacylglycerol (DAG). 
Hence, they supply substrates for lipid synthesis, but also act to regulate the intracellular concentration of  2 
key lipids during proinflammatory signaling, PA and DAG (16, 18, 19). Thus far, 3 different genes, LPIN1, 
LPIN2, and LPIN3, have been described that encode for lipin proteins with different patterns of  expres-
sion and function. The human and mouse gastrointestinal tract is the preferred tissue for the expression of  
LPIN3, while LPIN1 and LPIN2 are more highly expressed in other tissues (20). In an immune cell context, 
we have observed that the protein encoded by LPIN1, lipin-1, is primarily expressed in macrophages, where 
it influences TLR4-mediated events (16). Animals deficient in lipin-1 are protected from damage in models 
of  systemic inflammation, by experiencing a reduced production of  poised proinflammatory molecules 
(16). Interestingly, expression of  IL-23 seems to be one of  the proinflammatory factors most affected by 
lipin-1 during TLR4 activation of  murine and human macrophages (16).
Based on these previous findings, we have investigated in this work the possible role of  lipin-1 in the 
development of  colitis and colitis-associated tumorigenesis. Our data suggest that in the gut, lipin-1 may act 
to amplify inflammation, thereby supporting tumor progression and cancer development.
Results
Lipin-1 deficiency attenuates inflammation-promoted tumorigenesis and carcinogenesis in a murine colitis-associated 
cancer model. To investigate the role of  lipin-1 in colorectal tumorigenesis we used the well-known 
azoxymethane/dextran sodium sulfate (AOM/DSS) murine model, where tumor progression is driven 
by colitis (21). The carcinogenic progress in this model recapitulates the steps that take place during 
colitis-associated cancer in humans, from inflammation to dysplasia and then carcinogenesis (22). We 
observed that lipin-1–deficient animals lost significantly less weight than WT animals during treat-
ments (Figure 1A). Examination of  the colons at the end of  the protocol revealed a very significant 
decrease in the number of  tumors per animal, and in the percentage of  animals harboring tumors in 
lipin-1–deficient animals (Figure 1, B–D). The decrease in the number of  tumors affected both medial 
and distal colons (Figure 1, E and F). Also, the majority of  tumors from WT animals had a size of  2 to 
3 mm (45%), whereas the majority of  tumors from lipin-1–deficient animals were less than 2 mm (75%) 
(Figure 1, D, F, and G). A detailed histological examination of  tumor sections showed that, while in 
WT animals 46% of  the tumors were carcinomas, in lipin-1–deficient animals just 4% of  them were car-
cinomas (Figure 2A). Importantly, while 75% of  carcinomas were invasive in WT animals, we found no 
invasive carcinomas in lipin-1–deficient animals (Figure 2, A and B, and Supplemental Figure 1; supple-
mental material available online with this article; https://doi.org/10.1172/jci.insight.97506DS1). In 
agreement with these data, the average number of  mitoses in carcinomas from WT animals was nearly 
double that found in lipin-1–deficient animals (Figure 2C). Also, the proliferation marker Ki67 was 
more highly expressed in crypts from WT animals than from lipin-1-deficient animals (Figure 2D). 
Evaluation of  the presence of  the antiapoptotic protein Bcl-2 showed enhanced expression in tumors 
and in nontumoral tissue from WT animals compared with lipin-1–deficient ones, suggesting a reduced 
resistance to apoptosis in the phosphatase-deficient colons (Figure 2E).
Analysis of  mRNA levels for 3 well-known inflammatory protumorigenic factors, Il11, Il6, and Nos2, 
showed a relevant lower expression in tumors and adjacent areas from lipin-1–deficient mice compared 
with WT ones (Figure 2F and Supplemental Figure 1; protein data for IL-6 are shown in Supplemental 
Figure 2) (23). The same behavior was also found for Cxcl1 and Cxcl2, chemokines that are involved in the 
attraction of  immune cells, angiogenesis, and dysplasia-carcinoma transition events in colorectal cancer 
(Figure 2F; protein data for CXCL1 are shown in Supplemental Figure 2) (8, 24). In agreement with all of  
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these data, phosphorylation of  STAT3, a mediator of  epithelial proliferation that is activated by different 
cytokines, was increased in WT tissues from tumor-harboring mice relative to lipin-1–deficient ones (Fig-
ure 2, G and H) (25). These data suggest that lipin-1 positively influences tumor formation, growth, and 
progression in the large intestine.
Lipin-1 deficiency reduces macrophage infiltration in colon tumors. We next investigated the expression levels of  
lipin-1 in colon and colon tumors. In healthy murine colon tissues the expression of the phosphatase is not 
observable compared with the levels present in adipose tissue (Figure 3A). In tumors generated by AOM/DSS 
treatment, we observed that epithelial cells did not increase their lipin-1 content compared with normal epithe-
lial cells, and also that the latter do not show appreciable phosphatase levels compared with a positive control 
such as hepatic cells (Figure 3B). In fact, WT and lipin-1–deficient tumors with similar levels of dysplasia were 
alike regarding lipin-1 expression in the epithelial compartment (Figure 3E). However, we detected lipin-1 
expression in some stromal cells of the tumor, distinct from T or B lymphocytes (Figure 3, B and D). Because 
macrophages are a very important part of the stromal population that help in the growth and progression of  
tumors (1), we isolated tumor macrophages to study the expression of lipin-1 by immunoblot. As shown in 
Figure 3C, tumor macrophages express lipin-1 while, again, epithelial cells of the tumor do not.
Next, we evaluated the degree of  immune infiltration in the tumors, and we found that the infil-
tration of  F4/80+ cells (macrophages) was lower in animals deficient in lipin-1. The infiltration of  
other immune cells like T cells did not change in the absence of  the phosphatase (Figure 3, F and G). 
Furthermore, we observed that in the tumors generated in lipin-1–deficient animals there were fewer 
Figure 1. Lipin-1 deficiency decreases tumorigenesis in a murine model of colitis-associated cancer (CAC). WT and lipin-1–deficient (fld) animals were 
treated with AOM/DSS as described in the Methods. (A) Weight change along the protocol is shown. Two separate experiments were done with similar 
results (n = 13). Data represent the mean ± SEM. (B) Number of polyps in the large intestine per animal at day 80 (n = 13). (C) Percentage of animals with 
polyps (n = 13). (D) Representative open colons from WT and fld animals after AOM/DSS treatment. (E) Polyps per animal in medial and distal colons  
(n = 7–8). Data represent the mean ± SEM. (F) Images of representative distal colons after CAC induction. (G) Tumor diameter distribution in WT and fld 
animals (n = 7–8). *P < 0.05; **P < 0.01 by 2-way ANOVA with Tukey’s post hoc test (A) or Student’s t test (B and E).
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IL-6–producing macrophage-like cells than in tumors generated in WT animals, suggesting that these 
cells are less activated in the absence of  lipin-1 (Supplemental Figure 2).
Overall, these studies suggest that in the colon, lipin-1 expression is restricted to the stromal compart-
ment, with macrophages being part of  this lipin-1–expressing population, and that tumors from animals 
Figure 2. Lipin-1 deficiency decreases carcinoma development in colon. WT and lipin-1–deficient (fld) animals were treated with AOM/DSS and tumors were 
analyzed at day 80. (A) Percentage of histopathological lesions (carcinoma, Ca). (B) Microscopic images of dysplasias (×10), and carcinomas (×4) with magnified 
insets (×10). (C) Number of mitoses found in tumors (n = 3–6). Data represent the mean ± SEM. (D) Ki67+ cells/crypt analyzed in the nontumor part of the colons. 
More than 12 crypts/mice were scored (n = 5). (E) Images of nontumor and tumor parts of colons immunostained for Bcl-2. Original magnification was ×10, except 
for tumor images (×4). (F) Analysis by quantitative real-time PCR of the mRNA abundance of the indicated genes in tumors. Data represent the mean ± SEM. (G) 
Representative images of colons immunostained for phospho-STAT3. Original magnification was ×10. (H) Colon homogenates were analyzed for phospho-STAT3 
and β-actin by immunoblot (n = 4). *P < 0.05; **P < 0.01 by Student’s t test.
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Figure 3. Lipin-1 is expressed in tumor macrophages. (A) Homogenates from white adipose tissue (WAT) or normal colon tissue from WT animals 
were analyzed by immunoblot using specific antibodies against lipin-1 or β-actin as indicated. (B) Tumor contiguous sections from WT animals were 
stained with H&E (a) or stained by immunohistochemistry using specific antibodies against lipin-1 (b–e). Image panels show: (b) tumor epithelial 
cells, (c) normal epithelial cells, (d) tumor-infiltrating lymphocytes, (e) tumor stromal cells, and (f) liver (positive staining control for lipin-1). Original 
magnification, ×10 (a) and ×60 (b–f). (C) Homogenates from WAT, or isolated epithelial cells and macrophages from WT animal tumors were analyzed 
by immunoblot using specific antibodies against lipin-1 or GAPDH as indicated. (D) Tumor contiguous sections of the same tumor shown in B were 
stained by immunohistochemistry using antibodies against CD3e (T cells), CD45R (B cells), and lipin-1, as indicated. Original magnification, ×10 
and ×60 for magnified insets (right). (E) Colon and tumor sections from WT and lipin-1–deficient (fld) animals were stained by IHC using antibodies 
against lipin-1. Normal epithelial cells and tumoral epithelial cells are shown. Original magnification, ×60. (F) Contiguous tumor sections from WT 
and fld animals were stained by IHC using antibodies against F4/80 (macrophages) or CD3e (T cells). Original magnification, ×10. (G) Tumor F4/80+ 
and CD3e+ infiltrated cells were quantified from tumor sections stained as in F and data are shown as percentage of positive cells with respect to 
total cells. Cells were counted in 3 different fields per tumor (n = 6 for WT and 5 for fld). ***P < 0.001 by Student’s t test.
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deficient in lipin-1 have a decreased infiltration of  macrophages.
Lipin-1–deficient animals are protected against DSS-induced colitis. To further define the role of  lipin-1 in 
inflammation-driven tumorigenesis, a model of  UC induced by oral DSS was evaluated. DSS causes dis-
ruption of  the epithelial colonic layer, which is followed by translocation of  luminal bacteria to the mucosa 
and an acute inflammatory response marked by a massive infiltration of  the mucosa with neutrophils and 
macrophages (26). Clinical symptoms of  the disease are diarrhea, rectal bleeding, and weight loss that cor-
relate with the pathological changes in the colon (27). Treatment of  mice with 3% DSS promoted a severe 
weight loss in WT animals, but it affected lipin-1–deficient animals more modestly (Figure 4A). Disease 
activity index (DAI), which determines stool consistency and presence of  blood in the stools, also revealed 
that lipin-1–deficient animals had a less severe disease than WT ones (Figure 4B). A detailed histological 
analysis consistent with the gross findings showed that colonic injury was more aggressive and widespread 
in WT DSS-treated than in lipin-1–deficient DSS-treated mice (Figure 4, C–E). While the latter exhibited 
small, superficial, broad-based mucosal ulcers and moderate architectural distortion and/or destruction of  
glands, the former exhibited huge, superficial, broad-based mucosal ulcers and severe crypt damage with 
more than 75% of  crypts and surface epithelium lost. Taking into account all of  these features, the total 
histology score was much higher in WT animals than in lipin-1–deficient ones (Figure 4E). Furthermore, 
a hallmark of  proinflammatory signaling activation, phosphorylation of  ERK1/2 (also known as p44/42 
MAPK), was markedly reduced in colons deficient in lipin-1 (Figure 4F).
Because development of  DSS-induced colitis occurs along with an exacerbated production of  proinflam-
matory factors (26, 27), inflammatory gene expression was examined in DSS-treated animals. Compared 
Figure 4. Lipin-1–deficient animals are protected against DSS-induced colitis. WT and lipin-1–deficient (fld) animals were treated with 3% DSS. (A 
and B) Weight change and DAI score measured during DSS treatment. Experiments were performed 5 times (n = 5–10). Data represent the mean ± SEM. 
(C) Representative images of H&E-stained colon sections 8 days after DSS treatment initiation. Original magnification, ×10. (D and E) Colonic histology 
scores and total colonic histology score were calculated as indicated in the Methods (n = 5). Data represent the mean ± SEM. (F) Colon homogenates 
were analyzed for phospho-ERK1/2 (p-p44/42) and total ERK1/2 (p44/42) content by immunoblot. *P < 0.05; **P < 0.01;***P < 0.001 by 2-way ANOVA 
with Tukey’s post hoc test (A and B) or Student’s t test (D and E).
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with WT colons, tissues from lipin-1–deficient animals showed lower expression of  the genes Il6, Il23a, Nos2, 
Cox2, Tnf, Il1b, Cxcl1, and Il10, and their protein products (Figure 5, A and E, and Supplemental Figure 3), 
which are typically upregulated during inflammatory reactions by innate immune cells. Colons from lipin-1–
deficient animals were also found to exhibit lower levels of  the Th17 cell activation products Il17a and Il17f, 
and also of  the Th1-associated molecule Ifng, all of  which are known to be pathogenic in inflamed colon (Fig-
ure 5, B and D) (28). Interestingly, we observed an increased expression of  the Treg cell marker Foxp3 and the 
associated cytokine Tgfb in colons where lipin-1 was absent, a population of  CD4+ cells that helps maintain 
intestinal homeostasis (Figure 5C) (28, 29). These experiments suggest that lipin-1 impacts on proinflamma-
tory activation during the development of  DSS-induced colitis by increasing pathogenic innate and adaptive 
responses and restraining protective ones.
Histological evaluation of  inflammatory cell infiltration into the colon revealed that WT animals expe-
rienced a higher immune infiltration than that of  lipin-1–deficient ones during DSS treatment (Figure 5F). 
Closer analysis by flow cytometry showed that DSS-treated colons from lipin-1–deficient mice had signifi-
cantly reduced accumulation of  cells expressing the leukocyte marker CD45 (Figure 5G), the lymphocyte 
markers CD3 and CD4 (Figure 5H), and the myeloid cell markers CD11b and F4/80 (Figure 5I). There 
were no differences in the accumulation of  cells expressing CD45R, CD8, Gr1, or CD11c (Supplemental 
Figure 4). These data indicate that lipin-1 plays a role in immune infiltration during the development of  
colitis, allowing an increased lymphocytic and myeloid infiltration.
Expression of  lipin-1 in macrophages is sufficient to increase the severity of  colitis in lipin-1–deficient animals. 
Since innate immunity plays a key role in DSS-induced colitis (26, 27), and lipin-1 affected both the 
amount of  F4/80+ cells present in inflamed colons (Figure 5I) and the proinflammatory activation of  mac-
rophages (16), we investigated next whether lipin-1 expression in macrophages is intrinsically involved in 
the development of  colitis. To test this hypothesis we first isolated macrophages from the colons of  DSS-
treated animals and analyzed the production of  several cytokines that are involved in the development of  
colitis. We found that IL-1β, TNF-α, and IL-6 were all produced in lesser amounts by lipin-1–deficient 
colonic macrophages (Figure 6A). We also found that lipin-1–deficient macrophages displayed lower PA 
phosphohydrolase 1 (PAP-1) activity than WT ones (Figure 6B), a result that could explain the effects 
observed in cytokine production (16).
Secondly, we used adoptive transfer techniques (30, 31). Transference of  lipin-1–deficient macrophages 
into WT animals reduced disease severity, weight loss, and histology score during DSS treatment of  ani-
mals, albeit the effect did not reach statistical significance (Figure 6, C–F). However, transference of  WT 
macrophages into lipin-1–deficient mice promoted significant increases in weight loss, disease activity, and 
histology score that approached the levels observed for WT animals (Figure 6, C–F). This is consistent with 
the idea that WT macrophages possess an increased potential to produce damaging proinflammatory fac-
tors compared with macrophages deficient in lipin-1. Of  note, during the transference of  macrophages the 
animals still have their own macrophages, which explains why WT animals that received lipin-1–deficient 
macrophages still develop severe colitis.
Overall, these results suggest that selective expression of  lipin-1 in macrophages is sufficient to augment 
colitis severity.
Lipin-1 does not have an intrinsic role in T lymphocytes. Next, we investigated whether lipin-1 could also 
have an intrinsic role in the biology of  T lymphocytes that could partially explain the observed pheno-
type during colitis development in lipin-1–deficient animals. To this end, we studied the possible role of  
lipin-1 during T cell activation and proliferation by the classical engagement of  the T cell receptor–asso-
ciated complex CD3 and the costimulating receptor CD28. We observed that T cells deficient or not in 
lipin-1 responded equally well by expressing similar levels of  the inducible cell surface glycoprotein CD69, 
acquired during lymphoid activation (Supplemental Figure 5, A and B). Further, after 6 days of  activation, 
T cells expressing lipin-1 display the same proliferation levels as cells that do not express lipin-1 (Supple-
mental Figure 5, C and D).
Altogether, these data suggest that lipin-1 has no role in T cell activation and proliferation, which is in 
accordance with the low levels of  lipin-1 found in these cells compared with other immune cells such as 
macrophages (16). These data make it unlikely that T cell lipin-1 participates in the development of  colitis.
Reduced colitis in lipin-1–deficient animals is due to decreased IL-23 production. IL-23 plays an essential 
role in driving experimental colitis (28, 29) by supporting the expansion and maintenance of  Th17 cells 
(28), and restraining Foxp3+ Treg populations (25, 28). Because IL-23–associated responses (Th17- and 
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Figure 5. Lipin-1 deficiency reduces DSS-induced inflammation in colon. WT and lipin-1–deficient (fld) animals were treated with DSS as indicated 
in the Methods. (A–D) Analysis by quantitative real-time PCR of the mRNA content for the indicated molecules in colon tissues. The amount of each 
mRNA in the colons of untreated mice was given an arbitrary value of 1 (n ≥ 3). (E–I) Studies were performed at day 8 after treatment initiation. (E) 
Colon homogenates were used for cytokine quantification using specific ELISAs as indicated (n ≥ 3). (F) Histological evaluation of inflammatory cell 
infiltration into colonic tissues (n = 4). In A–F data represent the mean ± SEM. (G–I) Lamina propria cells were analyzed by flow cytometry. (G) Total 
leukocytes are shown as CD45+ cells (n = 4). (H and I) CD45+ cells were gated and total CD3+ and CD4+ cells (H) or total CD11b+ and F4/80+ myeloid cells 
(I) are shown (n = 4). *P < 0.05; **P < 0.01; ***P < 0.001 by Student’s t test.
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Treg-dependent cytokines), as well as Il23 mRNA levels, were affected by lipin-1 expression (Figure 
5, B and C), we assessed whether just restoring IL-23 levels could increase colitis severity in lipin-1–
deficient animals. To this end, recombinant IL-23 was administered daily to animals with or without 
DSS treatment. Exogenous IL-23 caused no mucosal damage to non–DSS-treated mice (Figure 7A and 
Supplemental Figure 6A). Of  note, treatment with IL-23 in combination with DSS induced a higher 
level of  transmural colonic damage, larger mucosal ulcers, and greater inflammatory cell infiltration 
than those in lipin-1–deficient mice treated with DSS only (Figure 7, A–D). Furthermore, administra-
tion of  IL-23 to DSS-treated lipin-1–deficient mice increased the levels of  mRNA for Il17a as well as 
other injury markers such as Tnf, Il1b, and the chemokines Cxcl1 and Ccl2 (Figure 7E). These effects 
Figure 6. Lipin-1 expression level in macrophages determines colitis severity. (A and B) Macrophages isolated from 
DSS-treated WT and lipin-1–deficient (fld) mouse colons were used for quantification of the indicated cytokines by spe-
cific ELISAs (n = 3) (A), or for quantification of PAP-1 activity, as indicated in the Methods (n = 4–6) (B). Data represent 
the mean ± SEM. (C–F) WT and fld animals were subjected to macrophage transference during the treatment with DSS, 
as mentioned in the Methods. Weight change (C), DAI score (D), total histology score (E), and images of H&E-stained 
colon sections (F) 8 days after DSS treatment initiation are shown (n = 4–5 animals/group). In E, data represent the 
mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 by Student’s t test (A and B) or 1-way ANOVA with Tukey’s post hoc 
test (C–E). In F, original magnification was ×10.
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were not found in IL-23–treated WT animals (Supplemental Figure 6). Moreover, administration of  
IL-23 during AOM/DSS treatment increased tumor loading in lipin-1–deficient animals (Figure 7F). 
These results suggest that the decreased production of  IL-23 in lipin-1–deficient animals is, at least in 
part, responsible for the lower level of  colonic damage encountered during DSS treatment, and also for 
tumor development.
Lipin-1 expression increases in human colon cancers and UC, and is a marker of  poor prognosis in inflammatory 
colon cancers. Next, we investigated whether our findings could be relevant to the pathogenesis of  human 
colon cancer and UC. First, we analyzed LPIN1 expression in relevant microarray data sets that are pub-
licly available. In 3 independent clinical data sets we found that LPIN1 expression levels were increased in 
adenocarcinomas when compared with corresponding paired adjacent mucosa, or compared with colon 
mucosa from healthy subjects (Figure 8, A and C, and Supplemental Figure 7, A and C) (32–34). We next 
investigated the correlation between the expression of  LPIN1 and several proinflammatory or chemokine 
genes. Interestingly, LPIN1 expression correlates with CXCL1 and CXCL2, with P less than 1 × 10–16 in some 
Figure 7. IL-23 increases susceptibility to DSS-induced inflammation in lipin-1–deficient animals. Lipin-1–deficient ani-
mals were treated with DSS, with or without a daily injection with 400 ng recombinant IL-23, for 6 days. (A) Representa-
tive images of H&E-stained colon sections. Original magnification, ×10. (B) Colonic histological scores (n = 5). (C) Colonic 
total histology score (n = 5). (D) Inflammatory cell infiltration into colonic tissues (n = 5). (E) Abundance of mRNA for the 
indicated genes analyzed by quantitative real-time PCR. The amount of each mRNA in colons treated with DSS only was 
given an arbitrary value of 1 (n = 4). (F) Tumors/animal after AOM/DSS treatment with or without IL-23 administration as 
indicated in the Methods (n = 4). Data in B–E represent the mean ± SEM. *P < 0.05; **P < 0.01 by Student’s t test.
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databases (Figure 8, B and C), and also strongly correlates with IL6, PTGHS2/COX2, NOS2, and IL23A in 
other databases (Supplemental Figure 7, B and D). We performed a meta-analysis of  relapse-free survival 
in 10 data sets comprising 1,251 patients (GSE38832, GSE17538, GSE37892, GSE41258, GSE39582, 
GSE14333, GSE33114, GSE12945, GSE31595, and GSE29621). We did not observe any relevant correla-
tion between LPIN1 expression level and relapse-free survival using all the tumors (Figure 8D). However, 
if  tumors were discriminated according to their cellular phenotype (247 tumors) (35), we found that high 
LPIN1 expression in inflammatory tumors significantly correlated with shorter relapse-free survival com-
pared with low-LPIN1-expressing tumors (Figure 8D). A similar behavior was also found for stem cell–like 
phenotype tumors (Figure 8D).
We also interrogated databases from patients with UC. In 2 independent data sets we found increased 
expression of LPIN1 in mucosa samples from UC patients compared with healthy subject samples (Supple-
mental Figure 8, A and C) (36, 37). Also, a significant positive correlation was found between the expression 
of  LPIN1 and the proinflammatory genes IL6 and NOS2 in those samples (Supplemental Figure 8, B and D).
Overall, these clinical results support the experimentally described role for LPIN1 in colonic inflam-
mation during tumor development and further indicate that it may function to favor cancer progression 
in an inflammatory context.
Figure 8. Expression pattern of LPIN1 in human UC and colorectal cancer and prognostic values in cancer. (A–C) Analysis performed in the GSE44076 
data set (246 colonic samples). (A) Box plots showing LPIN1 expression analysis in tissues from healthy donors (H, n = 50), and paired normal mucosa (N, 
n = 98) and tumor tissues (T, n = 98) from colorectal cancer patients. **P < 0.001 by 1-way ANOVA with Holm-Sidak post hoc test. (B) Scatter plot showing 
the correlation between LPIN1 and CXCL1 (left) or LPIN1 and CXCL2 (right) expression levels. Pearson’s coefficient tests were performed to assess statisti-
cal significance. (C) Schematic showing log expression levels for LPIN1, CXCL1, and CXCL2 in all the samples from the GSE44076 data set. (D) Kaplan-Meier 
plots of relapse-free survival (RFS) of patients as end point, stratified by expression of LPIN1. Analysis of the total number of samples (n = 1,211), or 
inflammatory (n = 45) or stem cell–like (n = 38) cancer subtypes are shown. P value was calculated by a log-rank test.
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Discussion
Inflammation, although necessary for damage repair and the battle against infections, can greatly impact 
proliferation, resistance to apoptosis, and cellular transformation to promote neoplasia. In fact, chron-
ic inflammation is now recognized as an enabling characteristic of  cancer. In the present study we have 
revealed how a lipid-related enzyme, lipin-1, modulates gut inflammation, and constitutes a pivotal player 
in the initiation and development of  tumorigenesis and carcinogenesis in an inflammatory context (Figure 
9). Also, our results show that the expression level of  LPIN1 has a prognostic value in human inflammatory 
and stem-like types of  colon cancers.
A striking finding of  our study is the observation that lipin-1 influences dysplasia-carcinoma transi-
tion events in mice. The effect may be due to the involvement of  lipin-1 in the expression of  CXCL1 
and CXCL2. These chemotactic factors are not only important for attracting immune cells, but are also 
related to angiogenesis and dysplasia-carcinoma transition processes in colon cancers (8, 24, 38, 39). 
Interestingly, one of  the factors that regulates CXCL1/2 levels in tumors seems to be PGE2 (8, 14), a 
proinflammatory lipid generated from COX-2, the expression of  which is also regulated by lipin-1 dur-
ing DSS-induced colitis. It is known that during tumor development CXCL1/2 may recruit CXCR2-
expressing myeloid-derived suppressor cells that have the capacity to inhibit CD8+ T cell cytotoxic 
activity against tumor cells, promoting in this way tumor growth and progression (8). Supporting our 
initial idea, we have also found a significant positive correlation between LPIN1 and CXCL1/2 expres-
sion in human carcinomas.
Lipin-1 expression in tumors likely participates in the production of  chemotactic factors CXCL1 
and CXCL2 and, as a consequence, in the infiltration of  myeloid cells (F4/80+, macrophages). Mac-
rophages are components of  the stromal compartment, where lipin-1 levels are the highest within the 
tumor. Since we have not found increased lipin-1 expression in colon tumoral epithelial cells versus nor-
mal epithelial cells, the aforementioned observation would explain the increased expression of  LPIN1 
in human colorectal carcinomas that is reported in databases.
Figure 9. Schematic representation of the role of lipin-1 in colitis and colitis-associated tumorigenesis. Lipin-1 participates in the production of 
proinflammatory factors that help define the level of inflammation in the gut subsequent to an insult. IL-23 production is regulated by lipin-1. This 
cytokine participates in the production of IL-17, and enhances the generation of chemokines that increase immune infiltration and help to increase 
gut damage. As a result, animals that express lipin-1 develop severe colitis when exposed to insult. If colitis is maintained over time, tumors and 
carcinomas develop in the colon. During tumorigenesis, lipin-1 determines the levels of cytokines such as IL-11 or IL-6 that affect tumor epithelial cell 
proliferation, and also chemotactic factors like CXCL1 or CXCL2 that aid in immune cell infiltration into the tumor. In fact, lipin-1 expression in human 
colon cancers correlates with the expression on these 2 chemotactic factors, and has a prognostic value for these patients. The level of expression of 
lipin-1 in colon macrophages seems to be key in all of these processes. 
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In other types of  human cancers such as prostate cancer or triple-negative breast cancer, increased 
lipin-1 expression levels have also been found relative to nontumoral tissues or to other types of  cancer (40, 
41). In fact, in triple-negative breast cancer there exists a positive correlation between LPIN1 expression in 
the tumor and poor prognosis for the patients, similar to what we have found in patients with colon cancer 
(40). However, in contrast to the colitis-associated cancer model that we have used, where tumor initiation 
and progression is mainly due to leukocyte infiltration and proinflammatory mediators (42), the initiation 
and progression of  prostate cancer or triple-negative breast cancer are not strongly based on inflammatory 
events. In these cancers the role of  lipin-1 seems to be relevant within the epithelial tumoral compartment 
regulating death/survival processes (40, 41). Although we cannot rule out that in human colon cancer 
lipin-1 also has a role in the maintenance of  tumoral epithelial cells, our data support the idea that lipin-1 
plays a role in the stromal/immune compartment during the development of  colitis-associated cancers. 
Further experimentation would be needed to elucidate whether lipin-1 expression in immune cells also 
plays a role in prostate and triple-negative breast cancers.
One of  the important findings in the present study is that LPIN1 expression has a prognostic value for 
relapse-free survival in inflammatory and stem cell–like types of  human colon cancers. The observation in 
human inflammatory colon cancers is supported by our experimental data in colitis and colitis-associated 
tumors in mice. However, the effect on a stem cell–like type of  cancer was more unexpected, but clearly 
supports the idea that the more LPIN1 expression is present in the tissue, the higher the inflammation and 
hence, the higher the probability for tumor cells generated from stem or stem-like cells to thrive. In such 
a scenario, LPIN1 expression would serve for stratification of  inflammatory and stem cell–like colorectal 
cancer patients, those with higher LPIN1 expression being the ones that would probably benefit the most 
from therapies to control inflammation.
During the development of  colitis, lipin-1 determines the level of  proinflammatory factors with high 
potential to influence the severity of  the disease, including IL-23 (28, 43). Among other effects, IL-23 is 
known to support the expansion and maintenance of  pathogenic Th17 cells and restrain Treg populations 
that help to maintain intestinal homeostasis (28, 43). The effect of  IL-23 on Th17 and Treg responses 
depends on the presence of  other important factors such as IL-6 and TGF-β (43). TGF-β favors Th17 
cell development in the presence of  IL-6, while in the absence of  IL-6, Treg cell expansion is favored 
(28, 43). Lipin-1 aids in the expression levels of  both IL-23 and IL-6, while it inhibits the expression of  
TGF-β. Thus, lipin-1, by regulating the TGF-β/IL-6 balance towards IL-6 in the presence of  IL-23 seems 
to favor IL-17 pathogenic responses over Treg ones. These considerations are further supported by the 
results obtained from lipin-1–deficient animals treated with exogenous IL-23 during DSS-induced colitis, 
where IL-23 enhances IL-17 expression levels and increases disease severity. IL-23 has already been used 
in clinical trials as a target for inflammatory bowel diseases or colon cancer, although no definitive results 
are yet available. It is clear that targeting this cytokine could have the advantage of  neutralizing pathogenic 
IL-17, but not protective IL-17 responses that are IL-23 independent in the gut (44). Based on our findings 
in human UC sample databases, we propose that stratification of  UC patients by LPIN1 expression could 
be a sound approach to improve the success of  therapies against IL-23.
Other proinflammatory factors such as Nos2/iNOS and Cox2/COX-2, whose expression depends on 
lipin-1, are also important for the development of  colitis (45, 46). In fact, combined treatment with inhibi-
tors for iNOS and COX-2 has maximal protective effect on chemically induced colitis models, supporting 
the idea that they might have some potential in the treatment of  inflammatory bowel diseases (47). Lipin-1 
could also exert its damaging effect via upregulation of  these 2 enzymes. Furthermore, we have previously 
shown that, in human macrophages, decreased expression of  lipin-1 blunts the activation of  group IVA cyto-
solic phospholipase A2 (14), the major enzyme regulating arachidonic acid mobilization from phospholipids 
for utilization by COX-2 (48). Thus, lipin-1 may regulate COX-2 activity by acting at 2 different levels, by 
controlling both the expression of  the enzyme and the availability of  substrate in inflammatory responses.
We demonstrate that lipin-1 greatly contributes to total cellular PA phosphatase activity of  colon mac-
rophages, indicating that the enzymatic activity of  the protein is important for the production of  proin-
flammatory cytokines by these cells and, as a consequence, in colitis development. Interestingly, lipins 
also display a transcriptional coactivator activity that has been well demonstrated in the liver (49). We 
cannot rule out at this time that the transcriptional coactivator activity of  lipin-1 plays a role in colitis and 
colon cancer, but there are several considerations that point to the idea that this might not be the case. For 
example, the PPAR transcription factors, downstream effectors of  nuclear lipin-1 activity, have been shown 
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to protect from colitis by repressing NF-κB, thereby reducing inflammation in murine models (50). Lipin-1, 
acting as a transcriptional coactivator, upregulates genes that are related to fatty acid oxidation and mito-
chondrial oxidative phosphorylation (49). These metabolic changes drive a macrophage antiinflammatory 
state (51). However, we show in this study and also in previous work (16) that, during colitis development, 
the greater the expression of  lipin-1 by macrophages, the higher their proinflammatory state. Regarding 
colon tumorigenesis, PPARγ inhibits polyp development in the colon in a AOM/DSS model (52), but the 
role of  other members of  the PPAR family is less clear, and contradictory information exists (53). In vitro 
studies have shown that the nuclear function of  lipin-1 does not restore the viability of  a lipin-1–deficient 
triple-negative breast cancer cell line (40). Taking into account that some lipin-1 roles may be cell specific 
(49), future investigation should shed light on the possible nuclear function of  lipin-1 during inflammatory/
tumorigenic processes in the gut.
It has been shown that some therapies against cytokines that are key in the development of  colon can-
cer, such as IL-6 (54) or TNF (55), have failed to produce clinical responses in recent trials. Taking this idea 
into account, it could be considered that inhibitors or treatments against molecules with the capacity to 
modulate multiple inflammatory pathogenic factors would have a higher probability of  success in the battle 
against cancer. We have shown in this study that one of  those molecules is lipin-1. Possible benefits that a 
therapy against lipin-1 could have include (a) inhibition of  the production of  CXCL1, CXCL2, IL-6, iNOS, 
and the potent tumorigenic factor IL-11, resulting in decreased immune infiltration and STAT3 activation; 
(b) reduction of  dysplasia-carcinoma transition events; and (c) reduction of  the levels of  the antiapoptotic 
protein Bcl-2. Also, and based on our results from DSS-induced colitis, it could be expected that a therapy 
against lipin-1, by restricting the expression of  cytokines like IL-23, could result in beneficial effects as well 
for patients suffering from inflammatory bowel diseases.
Methods
Animals. BALB/cByJ-Lpin1fld/J mice were purchased from The Jackson Laboratory and bred in the Service 
of  Animal Research and Welfare of  the University of  Valladolid, as previously described (16). Most of  the 
experiments were conducted with 12-week-old female animals.
Colitis induction. Acute experimental colitis was induced by adding 3% (w/v) DSS, 36–50 kDa (MP 
Biomedicals, Inc.) to drinking water. Fresh DSS solution was prepared daily. Six days after initiation of  
treatment, animals were just kept on regular drinking water for 2 additional days. Control groups received 
regular drinking water during the whole experiment. Body weight and DAI were evaluated daily as an 
indirect measure of  colitis severity. DAI was evaluated as the combined scores of  weight loss, stool con-
sistency, and fecal blood (27). At day 3 or 8 after induction of  colitis, mice were sacrificed under ketamine 
and xylazine (100 mg/kg and 10 mg/kg, respectively) and cervical dislocation. The abdominal cavity was 
exposed and colons were removed, washed with PBS, and cut into pieces for further molecular analysis or 
fixed for histological examination.
Colitis-associated tumor induction. Tumor induction was assessed as previously described with minor modi-
fications (21). Briefly, 12-week-old mice were i.p. injected with 7.5 mg/kg AOM (Sigma-Aldrich), and 5 days 
later they were treated with 3% DSS in drinking water for 5 days, followed by 15 days of  regular drinking 
water. DSS treatment was repeated twice (total of  3 cycles). One month after the last DSS cycle (80 days 
from the initiation of  the protocol) mice were sacrificed and polyps were counted and measured with a digi-
tal caliper. Individual polyps were excised and processed for mRNA extraction or fixed in 10% buffered for-
malin for histological examination. To study the effect of  IL-23 administration in the generation of  tumors, 
animals were i.p. injected with 400 ng recombinant IL-23 (Biolegend) every other day during the 5 days of  
treatment with DSS, for 3 cycles. The rest of  the protocol for tumor induction was as described above.
Histological assessment of  colonic damage. Colon specimens from both DSS and AOM/DSS experiments 
were excised near the ileocecal junction, washed in saline serum, fixed in 10% buffered formalin, embedded 
in paraffin, cut (3- to 4-μm-thick sections) and stained with H&E. Histological images were captured using a 
wide-field DM2000 microscope equipped with a DFC295 color camera (Leica) at ×10 magnification. Coli-
tis scores were assigned based on the depth of  injury (score 0–3); regenerative and metaplastic changes in 
glandular epithelium — nuclear enlargement, increased mitotic activity, appearance of  occasional Paneth’s 
cells and/or marked decrease in cytoplasmic mucin (score 1–4); architectural distortion/irregular shape 
and/or destruction of  glands (score 0–4); superficial broad-based mucosal ulcers (score 0–3); and inflam-
matory infiltration (score 0–3) (56). The sum of  the average values obtained for each scoring was multiplied 
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by a factor indicating the percentage of  colonic length involved (score 0–4) (56). For immunohistochemical 
analysis, paraffin-embedded tissues were cut into 5-μm sections and stained with antibodies against F4/80 
(Bio-Rad, MCA497), Ki67 (Master Diagnostica, 0003110QD), Bcl-2 (Abcam, ab182858), phospho-STAT3 
(Cell Signaling Technology, 9145), CXCL1 (Mybiosource, MBS840366), IL-6 (eBioscience, MP5-20F3), 
lipin-1 (14), CD3e (Santa Cruz Biotechnology, sc-1127), and CD45R (BD Biosciences, 557390).
Isolation of  immune cells from lamina propria. Large intestines from animals treated for 6 days with DSS, 
followed by 2 days of  regular drinking water, were harvested, washed, and cut into 1-cm pieces. Tissues were 
then incubated in Ca2+- and Mg2+-free Hank’s Balanced Salt Solution (HBSS) with 5% FBS and 2 mM EDTA 
in an orbital shaker at 37°C for 30 minutes. Supernatants were then discarded and the remaining pieces were 
minced and incubated with 1.5 mg/ml collagenase IV (Sigma-Aldrich) under the same conditions as above 
for 30 to 40 minutes. Cells and tissue pieces were filtered with a 70-μm strainer. Cell suspensions were cen-
trifuged at 430 g for 5 minutes and pelleted cells used for flow cytometry or macrophage enrichment (57).
Intestinal epithelial cell isolation. The epithelial cell population was isolated as described elsewhere (58, 
59). Briefly, minced colon tissue was incubated vigorously at 37°C in 1 mM EDTA-HBSS to obtain dissoci-
ated crypt cells. Epithelial cells were then separated from mononuclear and red blood cells through a 50% 
Percoll gradient. The upper layer containing the epithelial cells was centrifuged and the pellet was resus-
pended in the following buffer: 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 4 mM EDTA, 100 μM Na2VO4, 
1 mM PMSF, protease inhibitor cocktail (Sigma-Aldrich), and 0.5% Triton X-100 for 30 minutes at 4°C. 
Thirty micrograms of  protein was used for protein expression analysis by immunoblot.
Flow cytometry. Isolated lamina propria immune cells were stained with fluorochrome-conjugated anti-
bodies specific for CD45 (30-F11), CD4 (RM4-5), CD8 (53-6.7), CD3 (17A2), CD11b (M1/70), CD11c 
(N418), F4/80 (BM8), Ly6Gr (RB6-8C5), and CD45r (RA3-6B2) (eBioscience), followed by flow cytom-
etry analysis using a Beckman Coulter Gallios flow cytometer, as previously described (16). The data were 
analyzed with Kaluza software (Beckman Coulter). The percentage of  positive cells for any membrane 
marker was always measured after gating the CD45+ population.
Real-time PCR. Total RNA from mouse tissues and cells was extracted using an RNeasy Mini Kit (Qia-
gen) and TRIzol reagent (Ambion), respectively. The cDNA templates were synthesized using M-MLW 
Reverse Transcriptase (Ambion) following the manufacturer’s instructions. Quantitative real-time PCR 
analysis was performed in a LightCycler 480 (Roche) with a KAPA SYBR FAST qPCR kit (Kapabiosys-
tems) and specific primers for Il6, 5′-TAGTCCTTCCTACCCCAATTTCC-3′ and 5′-TTGGTCCTTAGC-
CACTCCTTC-3′; Il12a, 5′-CAATCACGCTACCTCCTCTTTT-3′ and 5′-CAGCAGTGCAGGAATAAT-
GTTTC-3′; Il12b, 5′-TGGTTTGCCATCGTTTTGCTG-3′ and 5′-ACAGGTGAGGTTCACTGTTTCT-3′; 
Il23a, 5′-ATGCTGGATTGCAGAGCAGTA-3′ and 5′-ACGGGGCACATTATTTTTAGTCT-3′; 
Ccl2, 5′-AGGTCCCATGTCATGCTTCTGG-3′ and 5′-CTGCTGCTGGTGATCCTCTTG-3′; Nos2, 
5′-CCAAGCCCTCACCTACTTCC-3′ and 5′-CTCTGAGGGCTGACACAAGG-3′; Ptgs2, 5′-TGAG-
CAACTATTCCAAACCAGC-3′ and 5′-GCACGTAGTCTTCGATCACTATC-3′; Il1b, 5′-GCAACT-
GTTCCTGAACTCAACT-3′ and 5′-ATCTTTTGGGGTCCGTCAACT-3′; Tnf, 5′-ACGGCATGGATCT-
CAAAGAC-3′ and 5′-AGATAGCAAATCGGCTGACG-3′; Il17a, 5′-TTTAACTCCCTTGGCGCAAAA-3′ 
and 5′-CTTTCCCTCCGCATTGACAC-3′; Il17f, 5′-TGCTACTGTTGATGTTGGGAC-3′ and 5′-AAT-
GCCCTGGTTTTGGTTGAA-3′; Foxp3, 5′-GGCCCTTCTCCAGGACAGA-3′ and 5′-GCTGATCATG-
GCTGGGTTGT-3′; Tgfb, 5′-CTCCCGTGGCTTCTAGTGC-3′ and 5′-GCCTTAGTTTGGACAG-
GATCTG-3′; Ifng, 5′-ATGAACGCTACACACTGCATC-3′ and 5′-TCTAGGCTTTCAATGACTGTGC-3′; 
Il11, 5′-TGTTCTCCTAACCCGATCCCT-3′ and 5′-CAGGAAGCTGCAAAGATCCCA-3′; Cxcl1, 
5′-CTGGGATTCACCTCAAGAACATC-3′ and 5′-CAGGGTCAAGGCAAGCCTC-3′; Cxcl2, 5′-CCAAC-
CACCAGGCTACAGG-3′ and 5′-GCGTCACACTCAAGCTCTG-3′; and Gapdh, 5′-AGGTCGGTGT-
GAACGGATTTG-3′ and 5′-TGTAGACCATGTAGTTGAGGTCA-3′. Quantification of  relative tran-
script levels was determined using the comparative 2–ΔΔCT method and Gapdh as the housekeeping gene (16).
Macrophage transference. Bone marrow–derived macrophages (BMDMs) were obtained and differenti-
ated as previously described (16). One million BMDMs were injected in the mouse tail vein 1 day before 
and after induction of  colitis with DSS, as previously described (30).
Immunoblots. Colonic tissues were homogenized in 20 volumes of  the following buffer: 25 mM HEPES/
NaOH pH 7.4, 150 mM NaCl, 4 mM EDTA, 25 mM NaF, 1 mM Na2VO4, 1 mM PMSF, protease inhibitor 
cocktail (Sigma-Aldrich), 0.2% SDS, and 1% Nonidet P-40 at 4°C. Homogenates were then centrifuged at 
12,000 g for 10 minutes at 4°C. Protein from the supernatants (20 μg) was resolved in 10% SDS-PAGE and 
1 6insight.jci.org   https://doi.org/10.1172/jci.insight.97506
R E S E A R C H  A R T I C L E
transferred to PVDF membranes (Millipore). Membranes were blocked with 5% BSA in PBS for 1 hour and 
then treated with antibodies against phospho-p44/42 MAPK (Thr202/Tyr204; Cell Signaling Technology, 
9101), p44/42 MAPK (Cell Signaling Technology, 4695), phospho-STAT3 (Tyr705, Cell Signaling, 9131), 
or lipin-1 (16) at 1:1,000 dilution, or with antibodies against GAPDH (Ambion, 4300) or β-actin (Sigma-
Aldrich, A5441) at 1:20,000 dilution in PBS with 5% BSA and 0.1% Tween. HRP-linked secondary antibod-
ies (GE Healthcare) were then used at 1:5,000 dilution. Specific proteins were visualized using ECL chemilu-
minescent substrate (GE Healthcare).
Cytokine determination in colon tissue and macrophages. Cytokine quantification in colon tissue was per-
formed as previously described (60). Colon tissues from animals treated with DSS were homogenized in 2 
volumes of  the following buffer: 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 4 mM EDTA, 100 μM Na2VO4, 
1 mM PMSF, protease inhibitor cocktail (Sigma-Aldrich), and 0.5% Triton X-100 for 30 minutes at 4°C. 
After centrifugation at 16,000 g for 10 minutes at 4°C, 500 μg of  the homogenate was used for quantifi-
cation of  IL-1β, IL-6, IL-23, and TNF-α by specific ELISAs (Invitrogen) following the manufacturer’s 
instructions. Cell-associated cytokines were measured in macrophages isolated from colon after homog-
enization with the above-mentioned buffer and 100 μg of  the homogenate used for ELISA quantification.
PAP-1 activity. PAP-1 activity was measured exactly as described elsewhere (61). The [14C]DAG product 
was separated by thin layer chromatography, scraped, and quantified by scintillation counting (62).
Clinical data set analysis. GEOquery package was used to download GSE44076 (32), GSE41328 (33), 
GSE4183 (34) data sets and annotations related to colon cancer, and GSE9452 (36) and GSE6731 (37) data sets 
related to UC from the Gene Expression Omnibus. Differences in LPIN1 expression were assessed by Student’s t 
test without the assumption of equal variance. Pearson’s correlation coefficients between LPIN1 and other genes 
were calculated with the function cor implemented in the R Stats package (version 3.0.2). For survival analyses, 
a database comprising independent colon cancer data sets was set up as described previously (63). Cox propor-
tional hazards regression was computed and Kaplan-Meier plots were drawn using relapse-free survival data. In 
this, patients were stratified into 2 cohorts by LPIN1 expression levels using the median expression as a cutoff. 
The data were tested for significance using log-rank tests and are represented as Kaplan-Meier plots.
Statistics. Data are represented as mean ± SEM. Statistical significance was determined by 1-way or 
2-way ANOVA with Tukey’s post hoc test or 2-tailed Student’s t test. For analysis of  human databases, 
1-way ANOVA with Holm-Sidak post hoc test or Pearson’s coefficient tests were performed to assess statis-
tical significance. In Kaplan-Meier plots, P value was calculated by a log-rank test. P < 0.05 was considered 
statistically significant.
Study approval. This study was approved by the Bioethics Committee of  the Spanish National Research 
Council (CSIC) prior to its commencement. All procedures involving animals were undertaken under the 
supervision of  the Institutional Committee of  Animal Care and Usage of  the University of  Valladolid, 
and are in accordance with the guidelines established by the Spanish Ministry of  Agriculture, Food, and 
Environment and the European Union.
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